Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acutus Medical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Takeo Mukai

İcra Kurulu Başkanı

US$496.8k

Toplam tazminat

CEO maaş yüzdesi	65.1%
CEO görev süresi	2.2yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Feb 24

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Dec 20

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Jul 18

Acutus files for FDA approval of catheter ablation system AcQBlate

Oct 18

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Aug 11

Acutus Medical sees Q2 revenue above consensus estimate

Jul 21

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Apr 06

Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report

May 15

CEO Tazminat Analizi

Takeo Mukai'un ücretlendirmesi Acutus Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$497k	US$323k	-US$12m

Tazminat ve Piyasa: Takeo 'ın toplam tazminatı ($USD 496.85K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 677.23K ).

Tazminat ve Kazançlar: Takeo şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Takeo Mukai (43 yo)

2.2yrs

Görev süresi

US$496,847

Tazminat

Mr. Takeo Mukai serves as Chief Financial Officer (CFO) at Acutus Medical, Inc. since January 9, 2023 and serves as its Chief Executive Officer since January 2024 and served as its Senior Vice President si...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Sheridan	Independent Director	3.6yrs	US$82.70k	0.035% $ 1.3k
David Bonita	Independent Director	8.6yrs	US$68.70k	0.042% $ 1.5k
Niamh Pellegrini	Independent Director	3.2yrs	US$75.70k	0.038% $ 1.4k
Andrew ElBardissi	Independent Director	7.3yrs	US$70.70k	0.042% $ 1.5k
Shaden Marzouk	Independent Chairperson of the Board	4.4yrs	US$73.70k	0.042% $ 1.5k
Jason Garland	Independent Director	2.2yrs	US$78.70k	0.016% $ 569.3

4.0yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AFIB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Acutus Medical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024

Acutus Medical, Inc. Announces Board Changes

Acutus Medical, Inc. Announces Chief Executive Officer Changes

Acutus Medical, Inc. Announces Executive Changes

High number of new directors

High number of new directors

Recent updates

Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting

Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index

Acutus Medical Provides Non-Compliance Update

Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022)

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Acutus Medical, Inc. Announces Board Changes

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Acutus Medical, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022)

Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acutus Medical Receives A Letter from Nasdaq Approving the Company’s Application to List Its Securities on the Nasdaq Capital Market

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Acutus Medical, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Acutus Medical Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Announces Results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$4.13

Acutus Medical Achieves Eu Mdr Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

Acutus Medical, Inc. Announces Full Market Release of Next Generation Software Platform AcQMap 8.5

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Acutus Medical Receives Non-Compliance Notice From Nasdaq

High number of new directors

Acutus Medical, Inc. Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System

Acutus files for FDA approval of catheter ablation system AcQBlate

Glancy Prongay & Murray LLP Appoints Lead Counsel in Securities Class Action Against Acutus Medical, Inc

Acutus Medical, Inc. Announces Board Changes

Consensus forecasts updated

Price target increased to US$3.38

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Acutus Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

Acutus Medical, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Acutus Medical sees Q2 revenue above consensus estimate

Acutus Medical, Inc. announced that it has received funding from Deerfield Management Company, L.P. Series C

Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB).

Acutus Medical, Inc. Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System

Acutus Medical Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Acutus Medical, Inc. Completes Enrollment in Ide Trial with Its Acqblate® Force Sensing Ablation System

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$3.50

High number of new directors

Price target decreased to US$4.00

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Consensus revenue estimates fall by 25%

Full year 2021 earnings: EPS exceeds analyst expectations

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc

Acutus Medical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Director recently bought US$151k worth of stock

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.95 loss in 3Q 2020)

Price target decreased to US$16.40

Acutus Medical: A Name To Slowly Accumulate

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2021

Second quarter 2021 earnings released: US$1.02 loss per share (vs US$32.24 loss in 2Q 2020)

AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark

Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price

Acutus Medical, Inc. has completed a Follow-on Equity Offering in the amount of $77 million.